Warfarin Use in Hemodialysis Patients With Atrial Fibrillation: A Systematic Review of Stroke and Bleeding Outcomes

Overview

Journal Can J Kidney Health Dis

Publisher Sage Publications

Date 2017 Nov 3

PMID 29093823

Citations 8

Authors

Chieh Tsai

Laura Quinn Marcus

Priya Patel

Marisa Battistella

Affiliations

Soon will be listed here.

Abstract

Background: Given the lack of clear indications for the use of warfarin in the treatment of atrial fibrillation (AF) in patients on hemodialysis and the potential risks that accompany warfarin use in these patients, we systematically reviewed stroke and bleeding outcomes in hemodialysis patients treated with warfarin for AF.

Objective: To systematically review the stroke and bleeding outcomes associated with warfarin use in the hemodialysis population to treat AF.

Design: Systematic review.

Setting: All adult hemodialysis patients.

Patients: Patients on hemodialysis receiving warfarin for the management of AF.

Measurements: Any type of stroke and/or bleeding outcomes.

Methods: MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) via OVID (1946 to January 11, 2017), and EMBASE via OVID (1974 to January 11, 2017) were searched for relevant literature. Inclusion criteria were randomized controlled trials, observational studies, and case series in English that examined stroke and bleeding outcomes in adult population of patients (over 18 years old) who are on hemodialysis and taking warfarin for AF. Studies with less than 10 subjects, case reports, review articles, and editorials were excluded. Quality of selected articles was assessed using Newcastle-Ottawa Scale (NOS).

Results: Of the 2340 titles and abstracts screened, 7 met the inclusion criteria. Two studies showed an association between warfarin use and an increased risk of stroke (Hazard Ratio: 1.93-3.36) but no association with an increased risk of bleed (HR: 0.85-1.04), while 4 studies showed no association between warfarin and stroke outcomes (HR: 0.12-1.17) but identified an association between warfarin and increased bleeding outcome (HR: 1.41-3.96). And 1 study reported neither beneficial nor harmful effects associated with warfarin use.

Limitations: The major limitation to this review is that the 7 included studies were observational cohort studies, and thus the outcome measures were not specified and predetermined in a research protocol.

Conclusion: Our systematic review demonstrated that for patients with AF who are on hemodialysis, warfarin was not associated with reduced outcomes of stroke but was rather associated with increased bleeding events.

Citing Articles

Potential Association of Holidays on Internationalized Normalized Ratio in Warfarin-Users at a Multidisciplinary Clinic.

Ryu R, Bahjri K, Tran H Cardiol Res. 2023; 14(1):38-44.

PMID: 36896230 PMC: 9990547. DOI: 10.14740/cr1448.

The Next Evolution of HemoDialysis eXpanded: From a Delphi Questionnaire-Based Approach to the Real Life of Italian Dialysis Units.

Dellepiane S, Marengo M, DArezzo M, Donati G, Fabbrini P, Lacquaniti A Blood Purif. 2022; 51(11):943-952.

PMID: 35231902 PMC: 9808684. DOI: 10.1159/000522038.

Warfarin Use, Stroke, and Bleeding Risk among Pre-Existing Atrial Fibrillation US Veterans Transitioning to Dialysis.

Sy J, Wenziger C, Marroquin M, Kalantar-Zadeh K, Kovesdy C, Streja E Nephron. 2022; 146(4):360-368.

PMID: 35124673 PMC: 9262829. DOI: 10.1159/000521494.

Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation.

Defoe K, Wichart J, Leung K Can J Kidney Health Dis. 2021; 8:20543581211046079.

PMID: 34552757 PMC: 8450544. DOI: 10.1177/20543581211046079.

Warfarin is associated with the risk of vascular calcification in abdominal aorta in hemodialysis patients: a multicenter case-control study.

Sadioglu R, Ustuner E, Ergun I, Ecder S, Nergizoglu G, Keven K Turk J Med Sci. 2021; 51(5):2607-2615.

PMID: 34289653 PMC: 8742472. DOI: 10.3906/sag-2104-221.

References

Sood M, Larkina M, Thumma J, Tentori F, Gillespie B, Fukuhara S . Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int. 2013; 84(3):600-8. PMC: 3885984. DOI: 10.1038/ki.2013.170. View

Chan K, Lazarus J, Thadhani R, Hakim R . Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 2009; 20(4):872-81. PMC: 2663838. DOI: 10.1681/ASN.2008080824. View

Sood M, Komenda P, Sood A, Rigatto C, Bueti J . The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis?. Chest. 2009; 136(4):1128-1133. DOI: 10.1378/chest.09-0730. View

Li J, Wang L, Hu J, Xu G . Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: A systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis. 2015; 25(8):706-13. DOI: 10.1016/j.numecd.2015.03.013. View

Tan J, Liu S, Segal J, Alexander G, McAdams-DeMarco M . Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol. 2016; 17(1):157. PMC: 5073415. DOI: 10.1186/s12882-016-0368-6. View

Yodogawa K, Mii A, Fukui M, Iwasaki Y, Hayashi M, Kaneko T . Warfarin use and incidence of stroke in Japanese hemodialysis patients with atrial fibrillation. Heart Vessels. 2015; 31(10):1676-80. DOI: 10.1007/s00380-015-0777-7. View

Seliger S, Gillen D, Longstreth Jr W, Kestenbaum B, Stehman-Breen C . Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 2003; 64(2):603-9. DOI: 10.1046/j.1523-1755.2003.00101.x. View

Danziger J . Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol. 2008; 3(5):1504-10. PMC: 4571144. DOI: 10.2215/CJN.00770208. View

Wakasugi M, Kazama J, Tokumoto A, Suzuki K, Kageyama S, Ohya K . Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol. 2013; 18(4):662-9. DOI: 10.1007/s10157-013-0885-6. View

10.

Wang X, Tirucherai G, Marbury T, Wang J, Chang M, Zhang D . Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2015; 56(5):628-36. DOI: 10.1002/jcph.628. View

11.

Heidenreich P, Solis P, Estes 3rd N, Fonarow G, Jurgens C, Marine J . 2016 ACC/AHA Clinical Performance and Quality Measures for Adults With Atrial Fibrillation or Atrial Flutter: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2016; 68(5):525-568. DOI: 10.1016/j.jacc.2016.03.521. View

12.

Bolton C, Downs L, Victory J, Dwight J, Tomson C, Mackness M . Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001; 16(6):1189-97. DOI: 10.1093/ndt/16.6.1189. View

13.

Chan K, Lazarus J, Thadhani R, Hakim R . Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009; 20(10):2223-33. PMC: 2754104. DOI: 10.1681/ASN.2009030319. View

14.

Liu G, Long M, Hu X, Hu C, Liao X, Du Z . Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation: A Meta-Analysis of Observational Studies. Medicine (Baltimore). 2015; 94(50):e2233. PMC: 5058909. DOI: 10.1097/MD.0000000000002233. View

15.

Lee M, Saver J, Hong K, Wu Y, Huang W, Rao N . Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis: A Meta-Analysis. Medicine (Baltimore). 2016; 95(6):e2741. PMC: 4753914. DOI: 10.1097/MD.0000000000002741. View

16.

Shen J, Montez-Rath M, Lenihan C, Turakhia M, Chang T, Winkelmayer W . Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. Am J Kidney Dis. 2015; 66(4):677-88. PMC: 4584203. DOI: 10.1053/j.ajkd.2015.05.019. View

17.

Yagmur E, Frank R, Neulen J, Floege J, Muhlfeld A . Platelet Hyperaggregability is Highly Prevalent in Patients With Chronic Kidney Disease: An Underestimated Risk Indicator of Thromboembolic Events. Clin Appl Thromb Hemost. 2013; 21(2):132-8. DOI: 10.1177/1076029613490828. View

18.

Boccardo P, Remuzzi G, Galbusera M . Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004; 30(5):579-89. DOI: 10.1055/s-2004-835678. View

19.

Wallentin L, Lopes R, Hanna M, Thomas L, Hellkamp A, Nepal S . Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013; 127(22):2166-76. DOI: 10.1161/CIRCULATIONAHA.112.142158. View

20.

Nochaiwong S, Ruengorn C, Awiphan R, Dandecha P, Noppakun K, Phrommintikul A . Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016; 3(1):e000441. PMC: 4916629. DOI: 10.1136/openhrt-2016-000441. View